Isodiol introduces new CBD raw ingredient, Heneplex p200™, to meet the demand for CBD Beverages as mainstream retailers prepare for the anticipated approval of the U.S. Hemp Bill.
VANCOUVER, British Columbia, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6B.F) (the “Company” or “Isodiol”) is set to debut its newest CBD raw ingredient, Heneplex p200™, at Supply Side West in Las Vegas November 8th and 9th, 2018, booth 1557, to meet the new demand and market trend in the beverage sector.
Heneplex p200™ has the advantage of being far more versatile than traditional CBD hemp extracts and oils, which can be difficult to formulate and use to manufacture consumer good products. CBD hemp extract in an oil form sticks to just about everything, tastes bad to many users, and dissolves in few substances besides alcohols and oils. In short, formulating with CBD hemp extracts is challenging. p200™ by contrast, can simply be mixed into food and beverage products, almost without exception, including protein shakes, juices, soda, coffee, tea, baked goods or frozen goods, or simply added to a glass of water.
Management would also like to provide an update to its shareholders around the volatility of the stock and would like to address recent investor inquiries. The Company has not deviated from its business plan announced on June 29, 2018 and believes it is executing on its business strategies in each division with new revenue opportunities being added on a consistent basis. Further, management believes some of the Company’s business strategies are in front of market trends that will soon be recognized by the market, particularly as legalization continues to trend in a favourable direction in the United States and Mexico.
Due to recent developments with the US Hemp Bill, the Company has postponed plans of its previously announced Chinese facility expansion plans and has been focusing its resources and attention to the expected upcoming opportunities in the United States and Mexico.
On December 6, 2017, the Company announced the 100% acquisition of CN Pharma, located in Abbotsford, BC, a pharmaceutical manufacturing company. The Company believed that CN Pharma was in the latter stages of obtaining its Licensed Dealer (“LD”) status under the provisions of the Canadian Controlled Drugs and Substances, however many changes to regulatory guidelines have caused a delay. CN Pharma has reapplied for their licensing under these new cannabis regulations and is ready for inspection. The Company is hoping to receive additional feedback from Health Canada after inspection and believes CN Pharma remains in a position to obtain its license. CN Pharma will only be paid the $6,000,000 CDN in stock upon successful completion of obtaining the license.
The Company is monitoring the developing regulations surrounding CBD in Canada and believes it will be in a position for the distribution of its products in this market as regulations continue to change. Currently, the Company can supply CBD as an API to an LD in Canada from its subsidiary, BSPG Laboratories, LTD. The Company strongly believes the U.S. and other foreign markets such as the U.K. and Brazil will surpass the market opportunities in Canada that are currently getting stock market attention and as a result, Isodiol will continue to put much of its focus on the U.S. and markets outside of Canada.
Finally, the Company had previously announced its intention to up list to a major US Exchange and this intention has not changed. The Company continues to explore all of its options for a potential up listing. Further updates on this matter will be provided as they are available.
Follow Our Corporate Updates On Facebook: https://www.facebook.com/IsodiolInternationalInc/ and on Twitter: @Isodiolintlinc
Get Social with Our Brands:
https://www.facebook.com/isodiol/
https://www.instagram.com/isodiol/?hl=en
https://www.instagram.com/isosportnow/?hl=en
https://www.instagram.com/pot.o.coffee/
https://www.instagram.com/cbdxtreme/
https://www.instagram.com/shopbradleys/?hl=en
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
Media Contact:
Christopher Hussey
Director of Communications
media@isodiol.com
Forward-Looking Information: This news release contains “forward-looking information” within the meaning of applicable securities laws relating to statements regarding the Company’s business, products and future the Company’s business, its product offerings and plans for sales and marketing. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned not to place undue reliance on forward-looking information. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the Company’s products and plan will vary from those stated in this news release and the Company may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation and does not intend, to update any forward-looking statements or forward-looking information in this news release. Although the Company believes that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct and makes no reference to profitability based on sales reported. The statements in this news release are made as of the date of this release.
The CSE has not reviewed, approved or disapproved the content of this press release.